DECIBEL THERAPEUTICS, INC. Item 8.01 Other Events.
On
Patients enrolled in the Phase 1b clinical trial were randomized to receive one of two doses of DB-020 in one ear while the contralateral ear received placebo, enabling each patient to serve as their own control. Patients were administered DB-020 and placebo up to three hours prior to each cisplatin infusion. Consistent with the results of a Phase 1 clinical trial of DB-020 previously completed by the Company in healthy volunteers, data from the interim analysis demonstrated that DB-020 was well tolerated, with adverse events generally mild to moderate. In the data from the interim analysis, 88% of patients experienced ototoxicity in their placebo-treated ear, and of these patients, 87% were partially or completely protected from ototoxicity in their DB-020-treated ears.
The interim analysis includes data collected as of
Key findings from the interim analysis include the following:
• DB-020 was generally well tolerated, with mostly mild to moderate adverse
events and no significant safety issues observed.
• 14 of 19 patients reported ear pain in the ear treated with
DB-020, and 2 of 18 patients reported ear pain in the ear treated
with placebo. One patient received DB-020 in one ear and
discontinued participation in the trial before receiving placebo
in the contralateral ear.
• 2 of 19 patients reported tinnitus, which is a ringing in the ear,
in the ear treated with DB-020 and 8 of 18 patients reported
tinnitus in the placebo-treated ear. Patients reporting tinnitus
for the DB-020 and placebo treated ears included one patient who
reported bilateral tinnitus in both ears and one patient who
reported worsening of pre-existing tinnitus without specified
laterality in both ears.
• DB-020, administered prior to cisplatin, had no apparent effect on
systemic cisplatin levels.
• 13 of 17 (76.5%) patients experienced cisplatin-induced ototoxicity in
the placebo ear after the first cycle of cisplatin; 15 of 17 (88.2%)
patients experienced cisplatin-induced ototoxicity in the placebo ear by
the last evaluable test.
• Placebo-treated ears lost approximately 30 decibels ("dB") on
average from baseline in high frequencies, shifting patients from
normal or slight hearing loss to moderate hearing loss (two
hearing loss categories) on average.
• In the 15 patients who experienced ototoxicity in the placebo ear by the
last evaluable test, DB-020 protected 13 (87%) from ototoxicity in their
DB-020-treated ear.
• 8 of 15 (53.3%) were completely protected, and 5 of 15 (33.3%)
were partially protected. (Complete protection was defined as no
change in hearing from baseline in the ear that received DB-020
according to the ASHA ototoxicity criteria in the clinically
assessed range.)
• Ears treated with DB-020 lost approximately 8dB on average from baseline.
• DB-020 reduced cisplatin-induced loss of speech audibility by 80% as
measured by the Speech Intelligibility Index, suggesting treatment with
DB-020 may reduce the risk of needing assistive hearing devices after
receiving cisplatin.
The Company plans to report additional data from the interim analysis of the Phase 1b clinical trial at an upcoming medical conference.
About the Phase1b Clinical Trial
The Phase 1b clinical trial of DB-020 is an ongoing, randomized, double-blind, placebo-controlled, multicenter trial designed to determine safety and tolerability of transtympanic injections of DB-020 in cancer patients receiving high doses of cisplatin. Audiometric measurements are made at the baseline before the first cisplatin infusion, before each subsequent cycle of cisplatin, and at the end of treatment in order to assess cisplatin-induced
--------------------------------------------------------------------------------
ototoxicity. ASHA criteria for significant ototoxic change are defined as either a ?20 dB decrease at any one test frequency, ?10 dB decrease at any two adjacent frequencies, or loss of response at three consecutive frequencies where responses were previously obtained. Ototoxicity is evaluated from baseline to post-cisplatin administration timepoints in each ear and comparative ototoxicity measurements are made between the ears dosed with DB-020 and placebo in each patient. Partial protection is defined using ASHA ototoxicity criteria being applied to between ear changes.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than statements of
historical facts, contained in this Current Report on Form 8-K, including
statements regarding the Company's strategy, future operations, prospects,
plans, objectives of management, the therapeutic potential for the Company's
product candidates and preclinical programs constitute forward-looking
statements within the meaning of The Private Securities Litigation Reform Act of
1995. The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict,"
"project," "potential," "should," or "would," or the negative of these terms, or
other comparable terminology are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. The Company may not actually achieve the plans, intentions or
expectations disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of various important
factors, including: uncertainties inherent in the identification and development
of product candidates, including the conduct of research activities and the
initiation and completion of preclinical studies and clinical trials, the timing
of and the Company's ability to submit and obtain approval to initiate clinical
development of its program candidates, whether interim data from a clinical
trial will be predictive of the results of the trial and future clinical trials,
whether the Company's cash resources are sufficient to fund its foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
uncertainties related to the impact of the COVID-19 pandemic on the Company's
business and operations, as well as the risks and uncertainties identified in
the Company's filings with the
--------------------------------------------------------------------------------
© Edgar Online, source
